Effect of nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy on dysglycemia and insulin sensitivity in South African HIV-Infected Patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 57, Issue 4, 2011, Pages 284-289

  Dave, Joel A ^a   Lambert, Estelle V ^b   Badri, Motasim ^c   West, Sacha ^a   Maartens, Gary ^b   Levitt, Naomi S ^c  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

antiretroviral therapy; diabetes; dysglycemia; human immunodeficiency virus (HIV); impaired glucose metabolism

Indexed keywords

EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; AGE; ANTHROPOMETRY; ARTICLE; BODY COMPOSITION; BODY MASS; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FEMALE; GENDER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RISK FACTOR; SKINFOLD THICKNESS; SOUTH AFRICA; WAIST CIRCUMFERENCE;

ADULT; ANTI-HIV AGENTS; BLOOD GLUCOSE; FEMALE; HIV INFECTIONS; HUMANS; HYPERGLYCEMIA; INSULIN RESISTANCE; MALE; MULTIVARIATE ANALYSIS; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; SOUTH AFRICA;

EID: 79960027869     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318221863f     Document Type: Article

References (25)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS). 2008 Report on the Global AIDS Epidemic-Executive Summary. 2008. Available at: www.UNAIDS.org. Accessed April 22, 2010.
2. South African Department of Health. Country Progress Report on the Declaration of Commitment on HIV/AIDS. 2010 Available at: http:// data.unaids.org/pub/Report/2010/southafrica-2010-country-progress-report-en.pdf. Accessed September 20, 2010.
3. Samaras K. Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection. J Antimicrob Chemother. 2008;61:238-245.
4. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353:2093-2099. (Pubitemid 29278477)
5. Dagogo-Jack S. HIV therapy and diabetes risk. Diabetes Care. 2008;31: 1267-1268.
6. Carr A, Samaras K, Chisholm DJ, et al. Abnormal fat distribution and use of protease inhibitors. Lancet. 1998;351:1736.
7. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-F58. (Pubitemid 28190689)
8. Hruz PW, Murata H, Mueckler M. Adverse metabolic consequences of HIV protease inhibitor therapy: the search for a central mechanism. Am J Physiol Endocrinol Metab. 2001;280:E549-E553.
9. DeWit S, Sabin CA,Weber R, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care. 2008;31:1224-1229.
10. Goedecke JH, Dave JA, Faulenbach MV, et al. Insulin response in relation to insulin sensitivity: an appropriate beta-cell response in black South African women. Diabetes Care. 2009;32:860-865.
11. Utzschneider KM, Prigeon RL, Faulenbach MV, et al. Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care. 2009;32:335-341.
12. Pacini G, Mari A. Methods for clinical assessment of insulin sensitivity and beta-cell function. Best Pract Res Clin Endocrinol Metab. 2003;17: 305-322.
13. American Diabetes Association. Diagnosis and classification of diabetes. Diabetes Care. 2010;33(supp 1):S62-S69.
14. Zannou DM, Denoeud L, Lacombe K, et al. Incidence of lipodystrophy and metabolic disorders in patients starting non-nucleoside reverse transcriptase inhibitors in Benin. Antivir Ther. 2009;14:371-380.
15. Mutimura E, Stewart A, Rheeder P, et al. Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;46:451-455. (Pubitemid 350098696)
16. Manuthu EM, Joshi MD, Lule GN, et al. Prevalence of dyslipidemia and dysglycaemia in HIV infected patients. East Afr Med J. 2008;85:10-17.
17. Jemsek JG, Arathoon E, Arlotti M, et al. Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients. Clin Infect Dis. 2006;42:273-280. (Pubitemid 43054203)
18. Martinez E, Arnaiz JA, Podzamczer D, et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med. 2003;349:1036-1046. (Pubitemid 37087618)
19. Dube MP, Parker RA, Tebas P, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS. 2005;19:1807-1818. (Pubitemid 41546599)
20. Fisac C, Fumero E, Crespo M, et al. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS. 2005;19:917-925. (Pubitemid 40834934)
21. Ledergerber B, Furrer H, Rickenbach M, et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect Dis. 2007;45:111-119. (Pubitemid 46984626)
22. Maggiolo F. Efavirenz: a decade of clinical experience in the treatment of HIV. J Antimicrob Chemother. 2009;64:910-928.
23. Cameron DW, da Silva BA, Arribas JR, et al. A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J Infect Dis. 2008; 198:234-240. (Pubitemid 352019289)
24. Fleischman A, Johnsen S, Systrom DM, et al. Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. Am J Physiol Endocrinol Metab. 2007;292:E1666-E1673. (Pubitemid 47084702)
25. Gervasoni C, Ridolfo AL, Trifiro G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS. 1999;13:465-471.